Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | WDR5 | P61964 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.57 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.57 |
| ▸ | NPY1R | P25929 | 2/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | HTR3A | P46098 | 2/20 | 0.57 |
| ▸ | FASN | P49327 | 2/20 | 0.57 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | IDE | P14735 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28064578 | 0.99 | KMT2A (0.56) | KMT2ACYP2C9WDR5LMNAMAPT | |
| SCHEMBL29186335 | 0.87 | NPC1 (0.42) | KMT2ACYP2C9WDR5LMNAMAPT | |
| SCHEMBL27990433 | 0.86 | ALDH1A1 (0.45) | KMT2ACYP2C9WDR5LMNAMAPT | |
| SCHEMBL14988972 | 0.83 | MAPT (0.57) | KMT2ACYP2C9WDR5LMNAMAPT | |
| SCHEMBL18040452 | 0.83 | CYP2C9 (0.41) | KMT2ACYP2C9WDR5LMNAMAPT | |
| SCHEMBL18040453 | 0.79 | CYP2C9 (0.39) | KMT2ACYP2C9WDR5LMNAMAPT | |
| SCHEMBL23988369 | 0.73 | CYP2C9 (0.63) | KMT2ACYP2C9WDR5LMNAMAPT | |
| SCHEMBL5483850 | 0.73 | KMT2A (0.58) | KMT2ACYP2C9WDR5LMNAMAPT | |
| Rabeprazole SCHEMBL23337 | 0.73 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAMAPT | |
| Rabeprazole SCHEMBL23336 | 0.73 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102781419-A | Skin lightening compositions | ELC MAN LLC | 2012-11-14 | — | — | CN | claimed |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2021-03-09 | — | — | US | disclosed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| CN-101365476-A | Combination of a DPP-IV inhibitor and a gastrin compound | WARATAH PHARMACEUTICALS INC (CA) | 2009-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | KMT2A 3440/4885CYP2C9 245/4885WDR5 872/4885 |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | DSG1, DEGS1, PLA2G2E | KMT2A 3440/4885CYP2C9 245/4885WDR5 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.